Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL)

Status:
Active, not recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

REaCT ZOL will compare one 4 mg dose of Zoledronate vs. one 4 mg dose of Zoledronate given every 6 months for 3 years.

Phase 4

Ottawa Hospital Research Institute

Diphosphonates
Zoledronic Acid